Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: Asthma & Airway Disease Research Center, University of Arizona
Location: 1501 North Campbell Ave., Tucson, AZ 85724
Lead Doctor: Dr. Fernando Martinez
IRB Committee: This study has been reviewed and approved by the Boston Children’s Hospital Institutional Review Board

Background

Asthma can be the cause of many sick days and can be life threatening in some cases. Currently, there is no way to prevent the disease.

Xolair® (omalizumab) is a medication that is approved to treat moderate to severe allergic asthma among people 6 years of age and older. It works by blocking antibodies which control our body’s response to things such as pollen and mold which cause allergies and allergic symptoms.

This study investigates if Xolair®or placebo  can prevent the development of asthma in young childrenwheezing, and are at high risk of developing the disease. Participants are required to attend 33 study visits, at the research site, over a 4-year period and will be compensated for participation and travel.

Why Participate? 

• You and your child may help in the advancement and understanding of asthma and allergic diseases.
• You and your child may help in the development of new approaches for treatment and prevention of asthma.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Children aged 2 to 3 years who:

• Have had 2-4 wheezing episodes in the past year
• Have a parent or sibling diagnosed with asthma or any allergies.   
• Are able to attend 33 study visits at the research site over approximately 4 years.